Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $5.99, but opened at $6.26. aTyr Pharma shares last traded at $6.13, with a volume of 1,164,738 shares changing hands.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on ATYR. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company increased their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $20.20.
Read Our Latest Analysis on aTyr Pharma
aTyr Pharma Stock Performance
The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. The stock's 50 day moving average is $4.98 and its two-hundred day moving average is $3.98. The stock has a market cap of $496.09 million, a price-to-earnings ratio of -6.88 and a beta of 0.89.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. Analysts anticipate that aTyr Pharma, Inc. will post -0.91 earnings per share for the current fiscal year.
Institutional Trading of aTyr Pharma
A number of hedge funds have recently made changes to their positions in ATYR. Federated Hermes Inc. bought a new stake in shares of aTyr Pharma in the fourth quarter worth $53,093,000. Point72 Asset Management L.P. bought a new stake in shares of aTyr Pharma in the 4th quarter worth about $17,677,000. Octagon Capital Advisors LP lifted its position in shares of aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after purchasing an additional 2,652,000 shares during the last quarter. Tikvah Management LLC acquired a new position in aTyr Pharma in the fourth quarter worth about $8,908,000. Finally, Woodline Partners LP acquired a new position in aTyr Pharma in the fourth quarter worth about $6,092,000. Hedge funds and other institutional investors own 61.72% of the company's stock.
aTyr Pharma Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Recommended Stories
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access